Princess Margaret Hospital
Toronto, Ontario, Canada
30 recruiting
Showing 1–20 of 51 trials
Recruiting
Phase 3
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Non-small Cell Lung Cancer
Boehringer Ingelheim400 enrolled199 locationsNCT07195695
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled404 locationsNCT05920356
Recruiting
Phase 3
A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
Breast Neoplasm FemaleRadiotherapyCosmetic Outcome
Ontario Clinical Oncology Group (OCOG)910 enrolled30 locationsNCT05417516
Recruiting
Phase 1Phase 2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Genentech, Inc.285 enrolled52 locationsNCT07100106
Recruiting
Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.210 enrolled26 locationsNCT05800665
Recruiting
Phase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled31 locationsNCT07114601
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled291 locationsNCT06252649
Recruiting
Phase 1Phase 2
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC60 enrolled13 locationsNCT07227025
Recruiting
Phase 2
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC68 enrolled8 locationsNCT07586202
Recruiting
Phase 2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Multiple Myeloma
Canadian Myeloma Research Group75 enrolled7 locationsNCT05272826
Recruiting
Phase 3
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC1,203 enrolled172 locationsNCT07164443
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.590 enrolled152 locationsNCT06881784
Recruiting
Phase 1
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Colorectal, CancerNon-small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Eli Lilly and Company630 enrolled52 locationsNCT06586515
Recruiting
Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
Breast CancerLung CancerMelanoma+7 more
University Health Network, Toronto7,000 enrolled1 locationNCT07524114
Recruiting
Phase 1
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company677 enrolled82 locationsNCT05614739
Recruiting
Phase 1
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.500 enrolled21 locationsNCT06384352
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
End-stage Kidney Disease
CSL Behring3,110 enrolled548 locationsNCT05485961
Recruiting
Phase 1Phase 2
A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
Advanced Solid Tumors
LigaChem Biosciences, Inc.191 enrolled8 locationsNCT07460375
Recruiting
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
Atrial FibrillationConcomitant ProceduresPFA+1 more
Boston Scientific Corporation433 enrolled37 locationsNCT06686485
Recruiting
Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Peripheral T Cell Lymphoma
Acrotech Biopharma Inc.504 enrolled69 locationsNCT06072131